[go: up one dir, main page]

BR9507073A - Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto - Google Patents

Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto

Info

Publication number
BR9507073A
BR9507073A BR9507073A BR9507073A BR9507073A BR 9507073 A BR9507073 A BR 9507073A BR 9507073 A BR9507073 A BR 9507073A BR 9507073 A BR9507073 A BR 9507073A BR 9507073 A BR9507073 A BR 9507073A
Authority
BR
Brazil
Prior art keywords
central nervous
same
nervous system
treat
disease
Prior art date
Application number
BR9507073A
Other languages
English (en)
Inventor
Palle Jakobsen
Anders Kanstrup
Peter Faarup
H Preben Olesen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9507073A publication Critical patent/BR9507073A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9507073A 1994-03-14 1995-03-10 Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto BR9507073A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK29594 1994-03-14
PCT/DK1995/000115 WO1995025110A1 (en) 1994-03-14 1995-03-10 Heterocyclic compounds, their preparation and use

Publications (1)

Publication Number Publication Date
BR9507073A true BR9507073A (pt) 1997-09-09

Family

ID=8091942

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507073A BR9507073A (pt) 1994-03-14 1995-03-10 Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto

Country Status (18)

Country Link
US (1) US5536721A (pt)
EP (1) EP0750621B1 (pt)
JP (1) JPH09510223A (pt)
KR (1) KR970701719A (pt)
CN (1) CN1144529A (pt)
AT (1) ATE182333T1 (pt)
AU (1) AU697183B2 (pt)
BR (1) BR9507073A (pt)
CA (1) CA2185670A1 (pt)
CZ (1) CZ265096A3 (pt)
DE (1) DE69510928D1 (pt)
HU (1) HUT76543A (pt)
IL (1) IL112957A0 (pt)
MX (1) MX9604023A (pt)
NO (1) NO963850L (pt)
PL (1) PL316239A1 (pt)
WO (1) WO1995025110A1 (pt)
ZA (1) ZA952086B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509846A (ja) * 1995-07-31 1999-08-31 ノボ ノルディスク アクティーゼルスカブ ヘテロ環式化合物、それらの調製及び使用
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
AU3783497A (en) * 1996-08-09 1998-03-06 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
EP1005348A1 (en) 1996-09-27 2000-06-07 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
DE19801646A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte alpha,beta-annellierte Butyrolactone
DE19801636A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte bicyclische Lactone
DE19801647A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte beta,gamma-annellierte Lactone
AU2241400A (en) 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DK2083811T3 (en) 2006-11-22 2017-01-30 Clinical Res Ass Llc PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2544688B1 (en) 2010-03-02 2016-09-07 President and Fellows of Harvard College Methods and compositions for treatment of angelman syndrome
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
RU2451686C1 (ru) * 2010-12-27 2012-05-27 Александр Васильевич Иващенко ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ
CN108218897B (zh) * 2018-03-02 2020-12-11 湘潭大学 多取代硒吩并吲哚及衍生物及其合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464384A (en) * 1981-12-23 1984-08-07 Yamanouchi Pharmaceutical Co., Ltd. 2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
KR970701719A (ko) 1997-04-12
NO963850D0 (no) 1996-09-13
WO1995025110A1 (en) 1995-09-21
HU9602522D0 (en) 1996-11-28
PL316239A1 (en) 1997-01-06
DE69510928D1 (de) 1999-08-26
EP0750621A1 (en) 1997-01-02
MX9604023A (es) 1997-09-30
CZ265096A3 (en) 1997-06-11
JPH09510223A (ja) 1997-10-14
ATE182333T1 (de) 1999-08-15
HUT76543A (en) 1997-09-29
ZA952086B (en) 1996-09-16
CN1144529A (zh) 1997-03-05
EP0750621B1 (en) 1999-07-21
AU697183B2 (en) 1998-10-01
AU1945795A (en) 1995-10-03
US5536721A (en) 1996-07-16
CA2185670A1 (en) 1995-09-21
NO963850L (no) 1996-11-14
IL112957A0 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
UA44254C2 (uk) Похідні 4-(заміщеного феніламіно)хіназоліну, спосіб їх одержання, спосіб лікування і фармацевтична композиція
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BG101715A (bg) Тетрациклени спиросъединения,метод за тяхното получаване и приложението им като 5нт долу 1d рецепторни антагонисти
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
FR2743562B1 (fr) Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
EA200200262A1 (ru) Пиперазиновые производные и их применение в качестве противовоспалительных агентов
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
FI972086A7 (fi) Parannetun monilääkeresistenssiaktiivisuuden omaavat uudet aminohappoj ohdokset
MXPA02001340A (es) Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
DE60103050D1 (de) Spiro[2.4]heptanaminocarbonsäure und ihre derivate
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
BR9910130A (pt) Derivados de cubana como antagonistas de receptor de glutamato metabotrópico e processo para a sua preparação
MX9301197A (es) Derivados de indol.
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
BR9811348A (pt) Compostos derivados de indol, processo para preparação dos mesmos, e, composições farmacêuticas.
ES2184300T3 (es) Derivados de aminoacidos utiles para tratar el accidente vascular encefalico.

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law